231
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Procollagen III, N-terminal propeptide (PIIINP): establishment of reference intervals in Northern European adults and children using the MAGLUMI 800 chemiluminescence immunoassay

, &
Pages 389-393 | Received 10 Feb 2021, Accepted 08 May 2021, Published online: 31 May 2021

References

  • Heickendorff L, Zachariae H, Bjerring P, et al. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol. 1995;32(4):584–588.
  • Nagy Z, Czirják L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol. 2005;23:165–172.
  • Barker J, Horn EJ, Lebwohl M, on behalf of the International Psoriasis Council, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol. 2011;25(7):758–764.
  • Reek JMPA, Menting SP, Janssen WWL, et al. Procollagen-3 N-terminal peptide measurements for the detection of liver fibrosis in methotrexate-treated patients with psoriasis: daily practice use and clinical implications. Br J Dermatol. 2017;177(5):1454–1457.
  • Thiele M, Madsen BS, Hansen JF, et al. Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology. 2018;154(5):1369–1379.
  • Trivedi P, Cheeseman P, Portmann B, et al. Variation in serum type III procollagen peptide with age in healthy subjects and its comparative value in the assessment of disease activity in children and adults with chronic active hepatitis. Eur J Clin Invest. 1985;15(2):69–74.
  • Knudsen CS, Heickendorff L, Nexo E. Measurement of amino terminal propeptide of type III procollagen (PIIINP) employing the ADVIA Centaur platform. Validation, reference interval and comparison to UniQ RIA. Clin Chem Lab Med. 2014;52:237–241.
  • Dixon WJ. Processing data for outliers. Biometrics. 1953;9(1):74–89.
  • Boyd J. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guidelines. CLSI Document C28-A3. 2010;28(3):1–59.
  • Lahti A, Petersen PH, Boyd JC, et al. Partitioning of nongaussian-distributed biochemical reference data into subgroups. Clin Chem. 2004;50(5):891–900.
  • Westgard JO. Westgard Desirable Biological Variation Database 2019. Available from: https://www.westgard.com/biodatabase1.htm.
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–310.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.